retatrutide dosing phase 2 trial in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 a 9-week trip on retatrutide

A multidisciplinary approach ensures comprehensive support for both emotional and physical health

Claims about GLP-1 support rely on marketing language, placebo effects, or unproven ingredients rather than rigorous human trials

We monitor labs, hormonal markers, and clinical symptoms along the way to ensure were optimizingnot overwhelmingthe body

There are several reasons your doctor might recommend you avoid GLP-1s

Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden, American Journal of Managed Care (2024) FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes, Food & Drug Administration (2024) What is medical necessity

Our medication compatibility checker covers interactions among more than 40 specific conditions, medications, and weight-loss injections